Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 6 (2009), Issue 4 (April)

1. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.
   J Natl Cancer Inst, 101(7): 519-32. [Abstract] [Full-text]
2. Inhibition of androstenediol-dependent LNCaP tumour growth by 17alpha-ethynyl-5alpha-androstane-3alpha, 17beta-diol (HE3235).
   Br J Cancer, 100(7): 1068-72. [Abstract] [Full-text]
3. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening.
   Br J Cancer, 100(7): 1198-204. [Abstract] [Full-text]
4. Secreted Frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer.
   Br J Cancer, 100(7): 1165-74. [Abstract] [Full-text]
5. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality.
   Int J Cancer, 124(11): 2683-9. [Abstract] [Full-text]
6. Phenotypic characterization of the infiltrating immune cells in normal prostate, benign nodular prostatic hyperplasia and prostatic adenocarcinoma.
   Exp Mol Pathol, 86(2): 108-13. [Abstract] [Full-text]
7. Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer?
   BJU Int, 103(8): 1058-63. [Abstract] [Full-text]
8. Prostate-specific antigen 'bounce' after permanent 125I-implant brachytherapy in Japanese men: a multi-institutional pooled analysis.
   BJU Int, 103(8): 1064-8. [Abstract] [Full-text]
9. Evaluating and grading cystographic leakage: correlation with clinical outcomes in patients undergoing robotic prostatectomy.
   BJU Int, 103(8): 1108-10. [Abstract] [Full-text]
10. Regulation of prostate cancer progression by galectin-3.
    Am J Pathol, 174(4): 1515-23. [Abstract] [Full-text]
11. Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial.
    Lancet Oncol, 10(4): 370-80. [Abstract] [Full-text]
12. Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.
    Am J Pathol, 174(4): 1492-503. [Abstract] [Full-text]
13. Nitric oxide synthase gene polymorphisms and prostate cancer risk.
    Carcinogenesis, 30(4): 621-5. [Abstract] [Full-text]
14. Nedd4L expression is downregulated in prostate cancer compared to benign prostatic hyperplasia.
    Eur J Surg Oncol, 35(5): 527-31. [Abstract] [Full-text]
15. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors.
    Cancer Cell, 15(4): 283-93. [Abstract] [Full-text]
16. Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination.
    Cancer Cell, 15(4): 270-82. [Abstract] [Full-text]
17. Unraveling the complexities of androgen receptor signaling in prostate cancer cells.
    Cancer Cell, 15(4): 245-7. [Abstract] [Full-text]
18. Hypothermic nerve-sparing radical prostatectomy: rationale, feasibility, and effect on early continence.
    Urology, 73(4): 691-6. [Abstract] [Full-text]
19. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Clin Immunol, 131(1): 1-10. [Abstract] [Full-text]
20. Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy.
    Urology, 73(4): 881-6. [Abstract] [Full-text]
21. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Urology, 73(4): 860-5; discussion 865-7. [Abstract] [Full-text]
22. Effect of aberrant vasculature during cryosurgery for prostate cancer.
    Urology, 73(4): 754-5. [Abstract] [Full-text]
23. Chronic periglandular inflammation on prostate needle biopsy does not increase the likelihood of cancer on subsequent biopsy.
    Urology, 73(4): 845-9. [Abstract] [Full-text]
24. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection.
    Urology, 73(4): 850-5. [Abstract] [Full-text]
25. Radical prostatectomy after previous prostate surgery: effects on surgical difficulty and pathologic outcomes.
    Urology, 73(4): 856-9. [Abstract] [Full-text]
26. D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells.
    Biochem Biophys Res Commun, 382(1): 96-101. [Abstract] [Full-text]
27. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}.
    J Biol Chem, 284(15): 10004-12. [Abstract] [Full-text]
28. Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines.
    Cancer Lett, 278(1): 82-7. [Abstract] [Full-text]
29. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
    Cancer Invest, 27(4): 369-75. [Abstract] [Full-text]
30. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer.
    Oncogene, 28(14): 1714-24. [Abstract] [Full-text]
31. Tissue factor and VEGF expression in prostate carcinoma: a tissue microarray study.
    Cancer Invest, 27(4): 430-4. [Abstract] [Full-text]
32. Ejaculatory function after permanent 125I prostate brachytherapy for localized prostate cancer.
    Int J Radiat Oncol Biol Phys, 74(1): 126-32. [Abstract] [Full-text]
33. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
    J Urol, 181(5): 2320-5. [Abstract] [Full-text]
34. Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era.
    Int J Radiat Oncol Biol Phys, 74(1): 104-9. [Abstract] [Full-text]
35. Metabolic complications of androgen deprivation therapy for prostate cancer.
    J Urol, 181(5): 1998-2006; discussion 2007-8. [Abstract] [Full-text]
36. Prostate cancer screening and treatment in the transplant population: current status and recommendations.
    J Urol, 181(5): 2018-25; discussion 2025-6. [Abstract] [Full-text]
37. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume.
    J Urol, 181(5): 2064-70. [Abstract] [Full-text]
38. Hospice and emergency room use by disadvantaged men dying of prostate cancer.
    J Urol, 181(5): 2084-9. [Abstract] [Full-text]
39. Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population.
    J Urol, 181(5): 2071-5; discussion 2076. [Abstract] [Full-text]
40. Does transrectal ultrasound probe configuration really matter? End fire versus side fire probe prostate cancer detection rates.
    J Urol, 181(5): 2077-82; discussion 2082-3. [Abstract] [Full-text]
41. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy.
    Int J Radiat Oncol Biol Phys, 74(1): 115-25. [Abstract] [Full-text]
42. Regarding the focal treatment of prostate cancer: inference of the Gleason grade from magnetic resonance spectroscopic imaging.
    Int J Radiat Oncol Biol Phys, 74(1): 110-4. [Abstract] [Full-text]
43. Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids.
    Biomaterials, 30(16): 3020-7. [Abstract] [Full-text]
44. Immunohistochemical evaluation of prostate needle biopsies using saved interval sections vs new recut sections from the block: a prospective comparison.
    Am J Clin Pathol, 131(5): 683-7. [Abstract] [Full-text]
45. Intermediate-conductance Ca2+-activated K+ channels (IKCa1) regulate human prostate cancer cell proliferation through a close control of calcium entry.
    Oncogene, 28(15): 1792-806. [Abstract] [Full-text]
46. Reproducibility of plasma alkylresorcinols during a 6-week rye intervention study in men with prostate cancer.
    J Nutr, 139(5): 975-80. [Abstract] [Full-text]
47. Lack of comprehension of common prostate cancer terms in an underserved population.
    J Clin Oncol, 27(12): 2015-21. [Abstract] [Full-text]
48. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
    J Clin Oncol, 27(12): 2022-9. [Abstract] [Full-text]
49. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer.
    Urology, 73(5): S4-10. [Abstract] [Full-text]
50. Overview of pivotal studies for prostate cancer risk reduction, past and present.
    Urology, 73(5): S36-43. [Abstract] [Full-text]
51. Current prostate cancer treatments: effect on quality of life.
    Urology, 73(5): S28-35. [Abstract] [Full-text]
52. Risk of developing prostate cancer in the future: overview of prognostic biomarkers.
    Urology, 73(5): S21-7. [Abstract] [Full-text]
53. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.
    Urology, 73(5): S11-20. [Abstract] [Full-text]
54. Central quadrant procurement of radical prostatectomy specimens.
    Prostate, 69(7): 770-3. [Abstract] [Full-text]
55. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.
    Prostate, 69(7): 787-98. [Abstract] [Full-text]
56. Vasoactive intestinal peptide behaves as a pro-metastatic factor in human prostate cancer cells.
    Prostate, 69(7): 774-86. [Abstract] [Full-text]
57. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome.
    Prostate, 69(7): 761-9. [Abstract] [Full-text]
58. Prostatic soy isoflavone concentrations exceed serum levels after dietary supplementation.
    Prostate, 69(7): 719-26. [Abstract] [Full-text]
59. Over-expression of IkappaB-kinase-epsilon (IKKepsilon/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines.
    Prostate, 69(7): 706-18. [Abstract] [Full-text]
60. Malignancy arising in seminal vesicles in the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Prostate, 69(7): 755-60. [Abstract] [Full-text]
61. Protease-activated receptor-1 is upregulated in reactive stroma of primary prostate cancer and bone metastasis.
    Prostate, 69(7): 727-36. [Abstract] [Full-text]
62. Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
    Prostate, 69(7): 744-54. [Abstract] [Full-text]
63. Dysplasia of human prostate CD133(hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense.
    Prostate, 69(7): 689-98. [Abstract] [Full-text]
64. Human prostasomes contain chromosomal DNA.
    Prostate, 69(7): 737-43. [Abstract] [Full-text]
65. Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
    Int J Cancer, 124(12): 2989-96. [Abstract] [Full-text]
66. The relation of alpha-linolenic acid to the risk of prostate cancer: a systematic review and meta-analysis.
    Am J Clin Nutr, 89(5): 1558S-1564S. [Abstract] [Full-text]
67. Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis.
    Oncogene, 28(16): 1853-63. [Abstract] [Full-text]
68. A pain in the neck -- an unexpected complication of transrectal ultrasound and biopsy.
    Br J Radiol, 82(977): e92-4. [Abstract] [Full-text]
69. Id-1 expression in androgen-dependent prostate cancer is negatively regulated by androgen through androgen receptor.
    Cancer Lett, 278(2): 220-9. [Abstract] [Full-text]
70. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
    Am J Pathol, 174(5): 1869-79. [Abstract] [Full-text]
71. Global levels of histone modifications predict prognosis in different cancers.
    Am J Pathol, 174(5): 1619-28. [Abstract] [Full-text]
72. Suppressor of cytokine signaling (SOCS)-1 is expressed in human prostate cancer and exerts growth-inhibitory function through down-regulation of cyclins and cyclin-dependent kinases.
    Am J Pathol, 174(5): 1921-30. [Abstract] [Full-text]
73. The discovery of common recurrent transmembrane protease serine 2 (TMPRSS2)-erythroblastosis virus E26 transforming sequence (ETS) gene fusions in prostate cancer: significance and clinical implications.
    Adv Anat Pathol, 16(3): 145-53. [Abstract] [Full-text]
74. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan.
    Urology, 73(5): 1104-9. [Abstract] [Full-text]
75. Effect of nicardipine on renal function after robot-assisted laparoscopic radical prostatectomy.
    Urology, 73(5): 1056-60. [Abstract] [Full-text]
76. PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.
    Urology, 73(5): 935-9. [Abstract] [Full-text]
77. Are total prostate-specific antigen serum levels in cirrhotic men different from those in normal men?
    Urology, 73(5): 1032-5. [Abstract] [Full-text]
78. Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram.
    Urology, 73(5): 1098-103. [Abstract] [Full-text]
79. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Urology, 73(5): 1087-91. [Abstract] [Full-text]
80. DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.
    Urology, 73(5): 1092-7. [Abstract] [Full-text]
81. Magnetic resonance imaging is a complementary method to stereological measurement of testicular volume.
    Urology, 73(5): 1131-5. [Abstract] [Full-text]
82. PrLZ expression is associated with the progression of prostate cancer LNCaP cells.
    Mol Carcinog, 48(5): 432-40. [Abstract] [Full-text]
83. Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II.
    Prostate, 69(8): 874-85. [Abstract] [Full-text]
84. Purine-rich element binding protein (PUR) alpha induces endoplasmic reticulum stress response, and cell differentiation pathways in prostate cancer cells.
    Prostate, 69(8): 861-73. [Abstract] [Full-text]
85. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Prostate, 69(8): 895-907. [Abstract] [Full-text]
86. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence.
    Prostate, 69(8): 886-94. [Abstract] [Full-text]
87. MTHFR C677T polymorphism contributes to prostate cancer risk among Caucasians: A meta-analysis of 3511 cases and 2762 controls.
    Eur J Cancer, 45(8): 1443-9. [Abstract] [Full-text]
88. Effects of the sesquiterpene lactone parthenolide on prostate tumor-initiating cells: An integrated molecular profiling approach.
    Prostate, 69(8): 827-37. [Abstract] [Full-text]
89. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients.
    Prostate, 69(8): 799-809. [Abstract] [Full-text]
90. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.
    Prostate, 69(8): 810-9. [Abstract] [Full-text]
91. Significance of preoperative HbA1c level in patients with diabetes mellitus and clinically localized prostate cancer.
    Prostate, 69(8): 820-6. [Abstract] [Full-text]
92. Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR.
    Prostate, 69(8): 851-60. [Abstract] [Full-text]
93. Cancer risks in first-degree relatives of CHEK2 mutation carriers: effects of mutation type and cancer site in proband.
    Br J Cancer, 100(9): 1508-12. [Abstract] [Full-text]
94. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging.
    Radiology, 251(2): 408-14. [Abstract] [Full-text]
95. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.
    J Clin Oncol, 27(13): 2137-43. [Abstract] [Full-text]
96. Phase II study of sunitinib in men with advanced prostate cancer.
    Ann Oncol, 20(5): 913-20. [Abstract] [Full-text]
97. Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy.
    BJU Int, 103(9): 1168-72. [Abstract] [Full-text]
98. Serenoa repens extract targets mitochondria and activates the intrinsic apoptotic pathway in human prostate cancer cells.
    BJU Int, 103(9): 1275-83. [Abstract] [Full-text]
99. Clinical staging error in prostate cancer: localization and relevance of undetected tumour areas.
    BJU Int, 103(9): 1184-9. [Abstract] [Full-text]
100. The impact of training on service provision in laparoscopic radical prostatectomy.
     BJU Int, 103(9): 1231-4; discussion 1234-5. [Abstract] [Full-text]
101. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
     BJU Int, 103(9): 1179-83. [Abstract] [Full-text]
102. Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens.
     BJU Int, 103(9): 1190-4. [Abstract] [Full-text]
103. Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer.
     BJU Int, 103(9): 1256-69. [Abstract] [Full-text]
104. Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience.
     BJU Int, 103(9): 1173-8; discussion 1178. [Abstract] [Full-text]
105. Periprostatic nerve block (PNB) alone vs PNB combined with an anaesthetic-myorelaxant agent cream for prostate biopsy: a prospective, randomized double-arm study.
     BJU Int, 103(9): 1195-8. [Abstract] [Full-text]
106. The first 1000 cases of laparoscopic radical prostatectomy in the UK: evidence of multiple 'learning curves'.
     BJU Int, 103(9): 1224-30. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.